ECSP045351A - DOSAGE FORMS OF AZITHROMYCIN WITH REDUCED SIDE EFFECTS - Google Patents
DOSAGE FORMS OF AZITHROMYCIN WITH REDUCED SIDE EFFECTSInfo
- Publication number
- ECSP045351A ECSP045351A ECSP045351A ECSP045351A EC SP045351 A ECSP045351 A EC SP045351A EC SP045351 A ECSP045351 A EC SP045351A EC SP045351 A ECSP045351 A EC SP045351A
- Authority
- EC
- Ecuador
- Prior art keywords
- azithromycin
- alkalizing agent
- effective amount
- dosage form
- glyceryl
- Prior art date
Links
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title abstract 13
- 229960004099 azithromycin Drugs 0.000 title abstract 13
- 230000000694 effects Effects 0.000 title abstract 3
- 239000002552 dosage form Substances 0.000 title 1
- 230000003113 alkalizing effect Effects 0.000 abstract 6
- 239000003795 chemical substances by application Substances 0.000 abstract 6
- 239000006186 oral dosage form Substances 0.000 abstract 5
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 abstract 4
- 241000124008 Mammalia Species 0.000 abstract 4
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 abstract 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract 2
- 230000002496 gastric effect Effects 0.000 abstract 2
- 229940081618 glyceryl monobehenate Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229960000502 poloxamer Drugs 0.000 abstract 2
- 229920001983 poloxamer Polymers 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000010362 Protozoan Infections Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 229940100692 oral suspension Drugs 0.000 abstract 1
- 229940059096 powder for oral suspension Drugs 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Una forma de dosificación oral que comprende azitromicina y una cantidad eficaz de un agente alcalinizante. Preferiblemente, dicha forma de dosificación oral comprende una cantidad eficaz de un agente alcalinizante y un multiparticulado de azitromicina en el que dicho multiparticulado comprende azitromicina, una mezcla de monobehenato de glicerilo, dibehenato de glicerilo y tribehenato de glicerilo y un poloxámero. Típicamente, la forma de dosificación oral incluye cualquier medio de administración oral adecuado tal como un polvo para suspensión oral, un envase o sobrecito de dosis unitaria, un comprimido o una cápsula. Además se describe una suspensión oral que comprende azitromicina, una cantidad eficaz de un agente alcalinizante y un vehículo. Preferiblemente, la azitromicina está en forma multiparticulada en la que dicho multiparticulado comprende azitromicina, una mezcla de monobehenato de glicerilo, dibehenato de glicerilo y tribehenato de glicerilo y un poloxámero. También se describe un procedimiento para reducir los efectos secundarios gastrointestinales asociados a la administración de azitromicina a un mamífero, que comprende la administración de forma contigua de azitromicina y una cantidad eficaz de un agente alcalinizante a dicho mamífero en el que la frecuencia de efectos secundarios gastrointestinales es menor que la que se experimenta administrando una dosis igual de azitromicina sin dicho agente alcalinizante. Además se describe un procedimiento para tratar una infección bacteriana o protozoaria en un mamífero que lo necesite que comprende la administración de forma contigua a dicho mamífero de una dosis única de una forma de dosificación oral en la que dicha forma de dosificación oral comprende azitromicina y una cantidad eficaz de un agente alcalinizante. Adicionalmente se describen multiparticulados de azitromicina que comprenden azitromicina, un tensioactivo; y un vehículo farmacéuticamente aceptable.An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and a multiparticulate azithromycin in which said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate and a poloxamer. Typically, the oral dosage form includes any suitable oral administration medium such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule. In addition, an oral suspension comprising azithromycin, an effective amount of an alkalizing agent and a vehicle is described. Preferably, the azithromycin is in a multiparticulate form in which said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate and a poloxamer. A method is also described for reducing the gastrointestinal side effects associated with the administration of azithromycin to a mammal, comprising the contiguous administration of azithromycin and an effective amount of an alkalizing agent to said mammal in which the frequency of gastrointestinal side effects it is less than that experienced by administering an equal dose of azithromycin without said alkalizing agent. In addition, a method for treating a bacterial or protozoan infection in a mammal that needs it is described, which comprises administering contiguously to said mammal a single dose of an oral dosage form in which said oral dosage form comprises azithromycin and a effective amount of an alkalizing agent. Additionally multiparticulates of azithromycin comprising azithromycin, a surfactant are described; and a pharmaceutically acceptable vehicle.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52708403P | 2003-12-04 | 2003-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP045351A true ECSP045351A (en) | 2005-01-28 |
Family
ID=34699855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP045351 ECSP045351A (en) | 2003-12-04 | 2004-10-08 | DOSAGE FORMS OF AZITHROMYCIN WITH REDUCED SIDE EFFECTS |
Country Status (8)
| Country | Link |
|---|---|
| CN (1) | CN1697648B (en) |
| AP (1) | AP2218A (en) |
| AU (1) | AU2004216676B2 (en) |
| EC (1) | ECSP045351A (en) |
| GT (1) | GT200400183A (en) |
| TN (1) | TNSN05319A1 (en) |
| UA (1) | UA78793C2 (en) |
| ZA (1) | ZA200408075B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101340882B (en) * | 2005-12-22 | 2015-02-11 | 大塚制药株式会社 | Method for producing drug-containing wax-based particles, extruder used for the method, and sustained-release preparation containing cilostazol |
| CN103054813A (en) * | 2012-12-31 | 2013-04-24 | 广东先强药业有限公司 | Azithromycin oral sustained-release dry suspension and preparation method thereof |
| CN104177457A (en) * | 2013-05-23 | 2014-12-03 | 长春海悦药业有限公司 | Azithromycin drug raw material, and preparation and application thereof |
| US20180071261A1 (en) * | 2015-03-10 | 2018-03-15 | Lumos Pharma, Inc. | Cyclocreatine microsuspension |
| EP3576755A4 (en) * | 2017-02-02 | 2020-12-02 | McMaster University | BICARBONATE AS A POTENTIATOR FOR ANTIMICROBIAL INGREDIENTS |
| CN114213484A (en) * | 2021-12-21 | 2022-03-22 | 河北远征药业有限公司 | Tildipirosin 1, 2-propylene glycol solvent compound and preparation method thereof |
| CN115212173B (en) * | 2022-07-11 | 2024-10-15 | 上海现代药物制剂工程研究中心有限公司 | Ambroxol hydrochloride spherical sustained-release microparticles, preparation method and use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW271400B (en) * | 1992-07-30 | 1996-03-01 | Pfizer | |
| US5605889A (en) * | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
| CN1123279A (en) * | 1995-06-15 | 1996-05-29 | 沈家祥 | Azithmycin water-soluble salt, injection thereof and their usage |
| RU2283092C2 (en) * | 2002-02-01 | 2006-09-10 | Пфайзер Продактс Инк. | Dry granulated azithromicine compositions |
-
2004
- 2004-05-14 CN CN200480000209.2A patent/CN1697648B/en not_active Expired - Lifetime
- 2004-05-14 AU AU2004216676A patent/AU2004216676B2/en not_active Expired
- 2004-05-14 AP APAP/P/2004/003145A patent/AP2218A/en active
- 2004-05-14 UA UA20041210181A patent/UA78793C2/en unknown
- 2004-09-16 GT GT200400183A patent/GT200400183A/en unknown
- 2004-10-06 ZA ZA200408075A patent/ZA200408075B/en unknown
- 2004-10-08 EC ECSP045351 patent/ECSP045351A/en unknown
-
2005
- 2005-12-14 TN TNP2005000319A patent/TNSN05319A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004216676B2 (en) | 2011-06-16 |
| TNSN05319A1 (en) | 2007-07-10 |
| ZA200408075B (en) | 2007-01-31 |
| CN1697648B (en) | 2010-06-23 |
| AU2004216676A1 (en) | 2005-06-23 |
| GT200400183A (en) | 2005-10-24 |
| AP2218A (en) | 2011-04-20 |
| CN1697648A (en) | 2005-11-16 |
| UA78793C2 (en) | 2007-04-25 |
| AP2004003145A0 (en) | 2004-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045630A1 (en) | DOSAGE FORMS OF AZITHROMYCIN WITH REDUCED SIDE EFFECTS | |
| BR0112311A (en) | Active agent release compounds and compositions, unit dosage form, method for preparing said compositions and their use | |
| AR037255A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING OXIBUTININE | |
| RU2013121788A (en) | HIV REPLICATION INHIBITORS | |
| UY35624A (en) | USE OF HIGH DOSE PRIDOPIDINE TO TREAT HUNTINGTON'S DISEASE | |
| EA201200096A1 (en) | PHARMACEUTICAL COMPOSITION OF THE HYPATITIS VIRUS PROTEASE INHIBITOR INHIBITOR | |
| BR0114799A (en) | Cyanophenoxy carboxylic acid compounds and compositions for releasing active agents | |
| JP2016518387A5 (en) | ||
| HK1247822A1 (en) | Formulations for oral administration of active agents | |
| CR6458A (en) | VALDECOXIB COMPOSITIONS | |
| SG157406A1 (en) | Oral medicament for the modified release of at least one active principle, in multi-microcapsule form | |
| AR048431A1 (en) | GALENIC FORMULATIONS OF ORGANIC COMPOUNDS | |
| AR034900A1 (en) | USE OF AN EFFECTIVE AMOUNT OF A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT, WELL IN COMBINED FORM ONLY OR SEPARATELY, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF A COMPOSITION THAT INCLUDES AN EFFECTIVE AMOUNT OF A PDD AN EFFECTIVE AMOUNT | |
| BR0207872A (en) | Active agent release compound, composition, unit dosage form and method of administration | |
| CO6270217A2 (en) | GALENIC FORMULATIONS OF ALISQUIRENO AND VALSARTAN | |
| ECSP045351A (en) | DOSAGE FORMS OF AZITHROMYCIN WITH REDUCED SIDE EFFECTS | |
| AR046410A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR MODIFIED LIBERATION OF MODAFINILO | |
| AR047469A1 (en) | ANTIMICROBIAL PRESERVANTS TO ACHIEVE A MULTIPLE DOSE FORMULATION USING BETA CYCLODEXTRINES FOR LIQUID DOSAGE FORMS | |
| UY26459A1 (en) | 3,4-DIHIDROQUINAZOLINES 5,6-DISSTITUTED | |
| AR037543A1 (en) | METHOD FOR CANCER THERAPY AND PHARMACEUTICAL COMPOSITION | |
| RU2002126216A (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF LIVER FIBROSIS AND CIRROSIS | |
| AR037291A1 (en) | USE OF A SPECIFIC DOSE OF FONDAPARINUX SODIUM FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES | |
| ECSP003771A (en) | METHOD TO PREVENT DIARRHEA | |
| JP2004529893A5 (en) | ||
| ECSP024336A (en) | A PHARMACEUTICAL DOSE UNIT FORM OF THE TYPE OF RIGID CAPSULES CONTAINING LISINE CLONIXINATE, A PROCEDURE FOR PREPARATION AND THE USE OF SUCH DOSE UNIT AS ANALGESIC AND / OR INFLAMMATORY |